Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid

Molly K. Altman, Vashisht Gopal, Wei Jia, Shuangxing Yu, Hassan Hall, Gordon B. Mills, A. Cary McGinnis, Michael G. Bartlett, Guowei Jiang, Damian Madan, Glenn D. Prestwich, Yong Xu, Michael A. Davies, Mandi M. Murph

    Research output: Contribution to journalArticle

    27 Scopus citations

    Abstract

    Background: Although the incidence of melanoma in the U.S. is rising faster than any other cancer, the FDA-approved chemotherapies lack efficacy for advanced disease, which results in poor overall survival. Lysophosphatidic acid (LPA), autotaxin (ATX), the enzyme that produces LPA, and the LPA receptors represent an emerging group of therapeutic targets in cancer, although it is not known which of these is most effective.Results: Herein we demonstrate that thio-ccPA 18:1, a stabilized phosphonothionate analogue of carba cyclic phosphatidic acid, ATX inhibitor and LPA1/3 receptor antagonist, induced a marked reduction in the viability of B16F10 metastatic melanoma cells compared with PBS-treated control by 80-100%. Exogenous LPA 18:1 or D-sn-1-O-oleoyl-2-O-methylglyceryl-3-phosphothioate did not reverse the effect of thio-ccPA 18:1. The reduction in viability mediated by thio-ccPA 18:1 was also observed in A375 and MeWo melanoma cell lines, suggesting that the effects are generalizable. Interestingly, siRNA to LPA3 (siLPA3) but not other LPA receptors recapitulated the effects of thio-ccPA 18:1 on viability, suggesting that inhibition of the LPA3 receptor is an important dualistic function of the compound. In addition, siLPA3 reduced proliferation, plasma membrane integrity and altered morphology of A375 cells. Another experimental compound designed to antagonize the LPA1/3 receptors significantly reduced viability in MeWo cells, which predominantly express the LPA3 receptor.Conclusions: Thus the ability of thio-ccPA 18:1 to inhibit the LPA3 receptor and ATX are key to its molecular mechanism, particularly in melanoma cells that predominantly express the LPA3 receptor. These observations necessitate further exploration and exploitation of these targets in melanoma.

    Original languageEnglish (US)
    Article number140
    JournalMolecular Cancer
    Volume9
    DOIs
    StatePublished - Jul 9 2010

    ASJC Scopus subject areas

    • Molecular Medicine
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid'. Together they form a unique fingerprint.

  • Cite this

    Altman, M. K., Gopal, V., Jia, W., Yu, S., Hall, H., Mills, G. B., McGinnis, A. C., Bartlett, M. G., Jiang, G., Madan, D., Prestwich, G. D., Xu, Y., Davies, M. A., & Murph, M. M. (2010). Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Molecular Cancer, 9, [140]. https://doi.org/10.1186/1476-4598-9-140